Literature DB >> 16454835

HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and with normal controls.

Dermot Gleeson1, Steven Evans, Martin Bradley, Jayne Jones, Robert J Peck, Asha Dube, Emma Rigby, Ann Dalton.   

Abstract

OBJECTIVES: Predisposition to alcoholic liver disease (ALD) may be partly genetic. Heterozygosity for the HFE mutations C282Y and/or H63D has been associated with more severe disease in several liver conditions. Studies in ALD have not used controls matched for alcohol consumption and results have been conflicting.
METHODS: HFE genotyping was performed in two Caucasian heavy-drinking cohorts (>60 units/wk (M) or 40 units/wk (F) for >5 yr): (a) 254 patients with decompensated ALD (Child's grade B or C), (b) 130 controls with similar alcohol consumption but without liver disease. Results in males were also compared with those from another study of healthy male blood donors.
RESULTS: (1) Genotype distributions for the C282Y and H63D mutations were similar in ALD patients, heavy-drinking controls, and healthy blood donors. (2) ALD patients with and without HFE mutations had similar disease severity, age at presentation, and alcohol consumption. (3) Increased serum ferritin and % transferrin saturation were seen in 63% and 29% of ALD patients, regardless of HFE genotype; the increased % transferrin saturation was due to reduced unsaturated iron binding capacity, rather than increased serum iron. (4) Stainable liver iron was present in 52% of patients; grade was greater in patients with two HFE mutations than in those with one or with none. (5) Only the two C282Y homozygote patients had substantial iron overload.
CONCLUSIONS: Although serum iron abnormalities are common, C282Y and H63D mutation frequencies were not increased in heavy drinkers with decompensated liver disease. HFE mutations, although modestly influencing liver iron, do not predispose to clinically significant ALD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454835     DOI: 10.1111/j.1572-0241.2006.00439.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  HFE genetic variability and risk of alcoholic liver disease: A meta-analysis.

Authors:  Yan-Yan Xu; Yu-Han Tang; Xiao-Ping Guo; Jing Wang; Ping Yao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 2.  Alcoholic liver disease: pathogenesis and new targets for therapy.

Authors:  José Altamirano; Ramón Bataller
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-09       Impact factor: 46.802

Review 3.  Alcoholic Hepatitis: A Review.

Authors:  Nooshin Hosseini; Julia Shor; Gyongyi Szabo
Journal:  Alcohol Alcohol       Date:  2019-07-01       Impact factor: 2.826

Review 4.  The myths and realities of hemochromatosis.

Authors:  Melanie D Beaton; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2007-02       Impact factor: 3.522

Review 5.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

6.  Iron homeostasis and H63D mutations in alcoholics with and without liver disease.

Authors:  Mariana Verdelho Machado; Paula Ravasco; Alexandra Martins; Maria Rosário Almeida; Maria Ermelinda Camilo; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 7.  Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.

Authors:  Ji Ye Hyun; Seul Ki Kim; Sang Jun Yoon; Su Been Lee; Jin-Ju Jeong; Haripriya Gupta; Satya Priya Sharma; Ki Kwong Oh; Sung-Min Won; Goo Hyun Kwon; Min Gi Cha; Dong Joon Kim; Raja Ganesan; Ki Tae Suk
Journal:  Int J Mol Sci       Date:  2022-08-06       Impact factor: 6.208

Review 8.  Iron overload disorders.

Authors:  Christine C Hsu; Nizar H Senussi; Kleber Y Fertrin; Kris V Kowdley
Journal:  Hepatol Commun       Date:  2022-06-14

9.  Role of duodenal iron transporters and hepcidin in patients with alcoholic liver disease.

Authors:  Marketa Dostalikova-Cimburova; Kamila Balusikova; Karolina Kratka; Jitka Chmelikova; Vaclav Hejda; Jan Hnanicek; Jitka Neubauerova; Jana Vranova; Jan Kovar; Jiri Horak
Journal:  J Cell Mol Med       Date:  2014-06-03       Impact factor: 5.310

10.  Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls.

Authors:  Qing Ye; Bao-Xin Qian; Wei-Li Yin; Feng-Mei Wang; Tao Han
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.